Adherence to Community Acquired Pneumonia guidelines and patients outcomes in a peri-urban hospital in Natal, South Africa

Waheeba Madani¹, Halima Dawood²

¹ University of KwaZulu Natal, School of Health Science, Department of Clinical Medicine, Durban, South Africa
² University of KwaZulu Natal, Head of Clinical Unit, Infectious Diseases, Greys Hospital, Pietermritzburg, South Africa

Abstract
Introduction: Community-acquired pneumonia (CAP) is an important cause of mortality and morbidity worldwide. This issue is further exacerbated by the Human Immunodeficiency Virus (HIV) epidemic.

Methodology: The study was a retrospective, clinical record review of hospitalized patients (18 years and older) with a diagnosis of LRTI between the 1st of January 2012 and 31 December 2012, descriptive and comparable analysis was performed.

Results: Number of patients was 274; 142 (51.8%) males. The commonest final diagnosis was Pulmonary Tuberculosis (PTB) in 131 (47.8%) and CAP in 127 (46.4%). The case fatality rate was 25.5% (70/274) and was significantly associated with HIV infection (77.4%) (p < 0.01), CD4 cell count ≤ 200 cells (96.3), final diagnosis of TB (65.7%) (p < 0.01), female sex (57%) (p < 0.01), confusion (50%) (p < 0.01), age of 65 years or more (29%) (p < 0.01). CURB-65 score (Confusion, Urea more than 7mmol/l, Respiratory rate (RR) ≥30 breaths /min, low blood pressure (less than 90 mmHg systolic and 60mmHg diastolic) and age ≥ 65 years) was only documented in 4 % (11/274) patients. Only 63 patients (23%) met the admission criteria of two or more points when the CURB-65 score was calculated.

Conclusions: Failure to use the CURB-65 score resulted in an increase admission of patients presenting with LRTI. There was an increased case fatality rate in this high HIV prevalence setting.

Key words: Community acquired pneumonia; HIV; Tuberculosis.

J Infect Dev Ctries 2021; 15(9):1321-1327. doi:10.3855/jidc.12701

Copyright © 2021 Madani et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction
Community Acquired Pneumonia (CAP) remains a common serious and potentially fatal disease worldwide particularly in the very young or the old individuals [1-3]. In the United States, pneumonia and influenza continue to be a common cause of death [4]. It is estimated that 1.5 million people per year are affected and approximately 30% die in the first year following pneumonia [5]. The economic burden associated with CAP remains substantial at more than 17 billion dollars annually in the United States [4,6]. In South Africa, influenza and pneumonia is the sixth and seventh highest cause of death in 2015 and 2016 respectively, accounting for 4, 3% of deaths. In KwaZulu Natal, influenza and pneumonia was ranked the eighth common cause of death in 2016 with marked improvement from 2011 where it was the third leading cause of death accounting for 5% of deaths [7]. In addition to acute respiratory symptoms, the South African and international guidelines for the diagnosis and treatment of pneumonia recommend the use of a chest radiograph to assist in the confirmation of CAP diagnosis. Furthermore, the application of CURB-65 score is used to assess the severity of illness score to help decide whether to hospitalize patients and to guide diagnostic work up [8-10]. The CURB-65 severity score is one of the validated scores recommended by most guidelines [11].

Many studies examined the improvement in patient care such as a decrease in time to antibiotic administration, increase in the percentage of patients receiving antibiotics at emergency department (ED), decrease in hospital stay, decrease in mortality, and a reduction in health care resource utilization when the score is used [12,13]. Pulmonary infections is a cause of significant morbidity and mortality in HIV infected individuals [14]. Bacterial pneumonia is considered an important illness in HIV infected individuals [15]. The study was conducted at a peri-urban hospital where the population served has a high HIV seroprevalence. Most patients admitted to this hospital with acute respiratory symptoms are HIV infected or suspected to have HIV infection and although the
diagnosis of CAP is made in many cases there is always a need to exclude other opportunistic infections such as PTB and pneumocystis Jirovinii pneumonia (PJP). The study sought to determine the adherence to the use of severity of illness scores in the management of patients with respiratory symptoms as per South African management guidelines for CAP, patients outcomes and whether HIV infection which also affect the severity, presentation and outcome of CAP, has an effect in the adherence to the guidelines. Specific objectives of this study were to determine if severity of illness scores (CURB-65) was applied to identify high risk patients at presentation and to determine the final diagnosis and outcome of patients admitted with a diagnosis of LRTI.

Methodology

Study design and patients

The study is a retrospective clinical record review of consecutive adult patients (≥ 18 years) hospitalized with a diagnosis of lower respiratory tract infection from 1 January 2012 and 31 December 2012, at Edendale Hospital, Pietermaritzburg, KwaZulu Natal, South Africa. The hospital has 860 beds (440 regional and 420 district level beds) and runs a large outpatient internal medicine service [16].

Inclusion / exclusion criteria

All patients who were admitted with the diagnosis of LRTI were included in the study. Patients were excluded if a diagnosis of CAP was unlikely (e.g. known PTB patient, and cough for more than two weeks), or if the patient was transferred out of the medical wards for example to the intensive care unit (ICU), or if the patient was discharged recently from hospital where the possibility of hospital acquired pneumonia is high, or if they were involved in a clinical trial or they were for palliative care.

Using the data extraction demographic and clinical data from clinical records of adults 18 years and older admitted with a diagnosis of LRTI was reviewed.

Data collection

All cases with a provisional diagnosis of LRTI were identified from the admission record register. A list with the patient’s names and medical file numbers was made and submitted to the medical records department where the patients files were extracted using the patients file number. From the 486 patients identified with such diagnosis, medical records were obtained from 429, using the data extraction form the following information was obtained from the patients’ records by researcher, demographic characteristics, the respiratory symptoms and duration (cough, chest pain, shortness of breath), presence of other symptoms (Loss of weight, loss of appetite, etc.), data regarding HIV (status, use of anti-retroviral therapy (ART), CD4 count), the clinical data (blood pressure, heart rate, RR, body temperature, oxygen saturation, assessment of severity using CURB-65 criteria), radiological and laboratory data, initial diagnosis, HIV testing if status unknown, and final diagnosis and clinical outcome upon discharge was also collected.

Statistical analysis: Statistical Package for Social Sciences (SPSS) version 22 statistics software and STATSTICA software was used for data analysis. A descriptive and comparable analysis of variables was performed. Categorical variables were analyzed using the chi-square test. A p value of < 0.05 was considered statistically significant and 95% confidence intervals were calculated. Qualitative variables were expressed as absolute frequencies and percentages, while quantitative variables were summarized as mean and standard deviation.

Results

Baseline patient characteristics

Of the 486 patients identified, medical records were obtained for 429 (88.3%) patients (57 files were
missing). 155 patients were excluded from analysis as they did not meet the inclusion criteria of the study. The total number of patients included in the analysis was 274 (63.9%) (Figure 1).

Baseline patient characteristics are shown in Table 1. There was slightly more males (51.8%) than females (48.2%). The median age was 39 years (range 18-95 years). The majority of the patients (49.4%) were in the 20-40 years range.

CURB-65 score
The CURB-65 score was only documented in 11 of 274 (4%) patients. For those with no documented CURB-65 scores, the calculated scores and different mortality risk groups are presented in Table 2. Only 63 patients (23%) met the admission criteria of two or more points. Of this 12 patients (4.4%) were in the high risk group requiring ICU admission but only two were admitted to ICU.

HIV status and related information
There were 153 (55.8%) patients in whom HIV status was known at admission, of these 134 (48.9%) were HIV infected and 19 (6.9%) were not infected. HIV status was unknown in 121 (43.8%) patients. Of the HIV infected patients 76 (56.7%) were on ART at presentation and 76 patients knew their CD4 count at presentation.

HIV testing was requested in 78 patients during hospital stay. Of these 46 (16.7%) tested positive while 32 (11.7%) were negative for HIV infection. Overall 65.7% of patients were HIV infected and 18.6% HIV uninfected patients. Following discharge, 66 (36.6%) patients were referred to the local clinic for continuation of treatment. CAP was the second commonest diagnosis in 127(46.4%), while thirty-two (12%) patients were diagnosed with PJP (25 of them with both PJP and PTB).

Table 1. Base line clinical characteristics of patients (n = 274).

| Characteristics | All patients Number (274) |
|-----------------|--------------------------|
| Age (SD) years  | Mean = 45 (19)           |
| Gender          |                          |
| Male (%)        | 142 (51.8)               |
| HIV status (%)  |                          |
| Unknown         | 120 (43.8)               |
| Positive        | 134 (48.9)               |
| Negative        | 19 (6.9)                 |
| CD4 (cells/mm3) |                          |
| CD4 unknown     | 58 (43.3)                |
| <50             | 18 (6.6)                 |
| <100            | 15 (5.5)                 |
| <200            | 13 (4.7)                 |
| <350            | 12 (4.4)                 |
| >350            | 18 (6.6)                 |
| ART use (%)     |                          |
| On ART          | 76 (56.7)                |
| Not on ART      | 58 (48.9)                |
| Symptoms (%)    |                          |
| Cough           | 246 (89.8)               |
| Fever           | 73 (26.6)                |
| Chest pain      | 77 (28.1)                |
| Shortness of breath | 31 (11.3)            |
| Headache        | 4 (1.5)                  |
| Systolic BP     |                          |
| < 90 mmHg       | 31 (13.3)                |
| 90-139 mmHg     | 189 (69)                 |
| ≥ 140 mmHg      | 22 (8)                   |
| Not recorded    | 32 (11.7)                |
| Diastolic BP    |                          |
| < 60 mmHg       | 42 (15.3)                |
| 60 - 80 mmHg    | 168 (61.3)               |
| > 80 mmHg       | 31 (11.3)                |
| Not recorded    | 33 (12)                  |
| Outcomes        |                          |
| In hospital death | 70 (25.5)             |
| Discharged home | 189 (69)                 |
| Transferred to other hospital | 9 (2.2)           |
| Unauthorized discharge | 6 (2.2)            |
| ICU admission   | 2 (0.5)                  |

Table 2. CURB-65 variables and risk groups.

| CURB-65 variables | Number of patients (%) | CURB-65 score | Number of patients (%) |
|-------------------|------------------------|---------------|------------------------|
| Confusion          | 53 (19.3)              | 0-1 point (Low risk) | 211 (77)              |
| Urea>7 mmol        | 61 (22.3)              | 2 points (Intermediate risk) | 51 (18.6)            |
| Respiratory rate>30/min | 56 (20.4)            | > 2 points (High risk) | 12 (4.4)              |
| Systolic BP<90mmHg | 31 (11.3)              |               |                        |
| Diastolic BP>60 mmHg | 42 (15.3)            |               |                        |
| Age > 65years      | 47 (17.2)              |               |                        |
Table 3. Illustrating a comparison between the Initial and final diagnosis.

| Initial differential diagnosis | N (%) | Final diagnosis | N (%) |
|-------------------------------|-------|----------------|-------|
| CAP                           | 53 (19) | CAP            | 127 (46.4) |
| PTB                           | 14 (5)  | PTB            | 129 (47)  |
| CAP/PTB                       | 134 (49) | PJP            | 32 (12)   |
| CAP/PTB/PJP                   | 32 (11.7) | MDR-TB         | 2 (0.7)   |
| CAP/MDR-TB                    | 8 (3)   | CAP with bronchiectasis | 3 (1.1) |
| CAP/CCF                       | 15 (5.5) | CCF            | 3 (1.1)   |
| CAP/HAP                       | 2 (0.7)  | Pulmonary embolism | 1 (0.4)   |
| ASTHMA                        | 2 (0.7)  | TB pericarditis | 1 (0.4)   |
| PJP                           | 4 (1.5)  | SVC syndrome   | 1 (0.4)   |
| CAP/PE                        | 1 (0.4)  |                |         |
| CAP/Meningitis                | 5 (1.8)  |                |         |
| Malignant lesion              | 2 (0.7)  |                |         |
| CAP/TB pericarditis           | 1 (0.4)  |                |         |
| CAP/SVC syndrome              | 1 (0.4)  |                |         |

Table 4. Factors associated with death.

|                          | OR   | 95% CI       | P    |
|--------------------------|------|--------------|------|
| Female sex               | 0.846| 1.591-5.091  | < 0.01|
| Age ≥ 65                 | 1.482| 0.759-2.891  | < 0.01|
| HIV infection            | 1.481| 1.330-1.650  | < 0.01|
| Confusion                | 1.215| 1.125-1.310  | < 0.01|
| O2 saturation < 90 %     | 1.102| 0.804-1.582  | < 0.05|
| Sys BP ≤ 90              | 0.557| 0.452-0.687  | < 0.01|
| Dias BP ≤ 60             | 0.4  | 0.300-0.533  | < 0.01|
| Urea ≥ 7mmol             | 1.826| 0.705-2.334  | 0.06  |
| CD4 ≤ 200 (cell/ml)      | 0.111| 2.126-4.552  | < 0.01|
| Final diagnosis           | 2.782| 1.576-4.909  | < 0.01|

Table 5. Comparison between patients who died and those who were discharged home.

|                          | Died (%) | Discharged home (%) | P value |
|--------------------------|----------|---------------------|---------|
|                          | N = 70   | N = 189             |         |
| Female                   | 40 (57.1)| 92 (48.7)           | < 0.01  |
| Age ≥ 65 years           | 20 (29)  | 27 (14.2)           | 0.01    |
| HIV infected             | 54 (77.2)| 118 (62.4)          | < 0.01  |
| CD4 count (cells/mm) ≤ 200 | 52(96.3)| 18 (8.8)            | < 0.01  |
|                          | 2 (3.7)  | 38 (18.6)           | < 0.01  |
| Oxygen saturation <90%   | 20 (28.6)| 28 (15)             | 0.05    |
| Systolic BP ≤ 90mmHg     | 11 (16)  | 20 (10)             | < 0.01  |
| Diastolic BP < 60 mmHg   | 11 (16)  | 31 (16.4)           | < 0.01  |
| Confusion                | 35 (50)  | 18 (9)              | 0.001   |
| CURB-65 (documented)     | 2 (2.8)  | 9 (4.7)             | 0.56    |
| Final diagnosis           | 24 (33.3)| 103 (54.4)          | < 0.01  |
| CAP                      | 46 (65.7)| 83 (43.9)           | < 0.01  |
| Others                   | 0        | 3 (1.6)             |         |
Table 3 shows a comparison of the initial and final diagnosis. Patients who were diagnosed with CAP were more likely to be male (58.2% vs. 44%), have consolidation on the chest radiograph (44% vs. 29%) and less prominent chest infiltrates (30% vs. 52%) compared to those who had a diagnosis of PTB. The proportion of those with HIV infection was slightly lower in patients with CAP (39% vs. 47%), but there was no significant difference in outcome. Comparison between the two groups is presented in Table 6.

Outcomes and factors associated with death

Death occurred in 70 (25.5%) patients whilst 189 (69%) were discharged home. Nine cases (3.3%) were transferred to another hospital (pulmonology unit, cardiothoracic unit or MDR-TB hospital) and six patients (2.2%) left the hospital (unauthorized discharges). Death was significantly associated with HIV status \((p<0.01)\), CD4 cell count \((p<0.01)\), female sex \((p<0.01)\), age \(\geq 65 \) \((p<0.01)\), level of consciousness \((p=0.01)\), O₂ saturation \((p=0.05)\), low systolic and diastolic blood pressure \((p<0.01)\), blood urea \((P=0.06)\) and the final diagnosis of TB \((p<0.01)\).

HIV infection was more common in patients who died compared to those who survived (66% vs. 43%) \((p<0.01)\). There was a higher mortality in females (57.1% vs. 48.1%), people 65 years and older (29% vs. 14%) and those with low CD4 count and low systolic blood pressure. Those who died were more likely to be diagnosed with PTB (65.7 vs. 33.3). A comparison between the two groups is presented in Table 5.

Discussion

The CURB-65 score is a validated score that predicts CAP severity and both in-hospital mortality and risk of 30-day mortality [17]. It also enables an assessment of the need for mechanical ventilation, and the rate of hospital re-admission [18]. This study shows that CURB-65 score was not used to risk stratify patients prior to hospital admission, despite the individual variables that make up the score being documented and available in patient files. As a result; an increased number of patients were admitted resulting in an increased utilization of healthcare resources and increased cost of treatment. However, it is most likely that the score was not utilized because most of the patients were HIV infected with low CD4 cell counts and not on antiretroviral treatment at the time of presentation. The poor use of the score also resulted in a high risk patients who required ICU management to be identified (2/12).

Our study shows a high case fatality rate of 25% despite only 23% of patients meeting the admission criteria for CAP according to calculated CURB-65 score.

This discrepancy could be related to the high prevalence of HIV infection [19]. Many studies investigated the association between pneumonia and HIV infection and found that the incidence of pneumonia in HIV infected patients is five to tenfold higher than in HIV un-infected patients [20-22] and pneumonia is more severe and fatal in the presence of HIV infection [23].

The lack of validation of the CURB-65 score in areas with high HIV burden setting limits the utility in this setting. It is recommended that these scores be used only in HIV infected patients with a CD4 cells count more than 200 cell/ml while all patients with CD4 cell count less than 200 cell/ml be admitted to hospital [24]. In our study we found more than 96% of patients who died had CD4 cell count less than 200 cell/ml (Table 3). The South African CAP guidelines suggest that severity

---

Table 6. Comparison between the patients who had a final diagnosis of CAP and those who were diagnosed with PTB.

| CAP N = 127 (%) | PTB N = 131 (%) |
|----------------|-----------------|
| Male 74 (58.2) | 56 (42.8)       |
| Females 53 (42) | 75 (57.2)       |
| HIV infected 75 (59) | 99 (75.6)  |
| Pre TB 24 (19) | 25 (24)         |
| Confusion 16 (13) | 11 (11)      |
| Urea <7 mmol | 65 (51.2) | 47 (45.2) |
| ≥7mmol | 28 (22) | 14 (14) |
| Outcome Death | 24 (19) | 46 (35.1) |
| Discharged home 103 (81) | 83 (63.4) |
| HIV status Unknown 66(52) | 50 (38.2) |
| Positive 50 (39.3) | 73 (55.7) |
| Negative 11 (8.7) | 8 (7.7)     |
score should not be used as a sole determinant of site of care.

Gender is thought to play an important role in the incidence and outcomes of many diseases [25] and many studies investigated the association between female sex and outcomes in patients with sepsis, some showed that mortality was unaffected by gender [26]; whilst others found that for lung related sepsis, female sex is associated with severe disease and more mortality and have suggested adding female sex as risk factor for poor outcomes [27]. In this study we found that women constituted 57% of mortality.

We found around 17% of our study population were 65 years and older. In this age group, 20/47 (42.5%) died during their hospital stay. This accounted for one third of the mortality (Table 4). Several studies have found that age of 65 or more is a strong predictor of death in patients with LRTI, and this is independent of other components of CURB-65 score [28,29].

The findings of higher mortality of those with HIV infection and TB at increased risk of mortality is in keeping with other studies from Africa. TB is the commonest presenting illness in those with HIV infection and is the major contributor to HIV associated mortality [30]. South Africa is one of the countries with the highest TB burden and has the highest TB/HIV co-infection in the world according to World Health Organisation (WHO) reports between 2016 to 2018 [31,32].

The results reported herein should be viewed in the light of some limitations. Firstly, the retrospective study design resulted in missing data and hence may limit the generalisability of the findings. Secondly, some of the factors and co-morbidities strongly associated with mortality and morbidity in CAP such as tobacco smoking history, alcohol use, diabetes and chronic obstructive pulmonary disease (COPD) were not collected and included in the analysis. Another limitation is that the study did not report on the outcome of high risk patients who required admission to ICU but were treated in the general medical wards. Lastly although in the majority of patients PTB was confirmed smear positive TB, the diagnosis of CAP and PTB was a clinical diagnosis which might affect the accuracy of results and contribute to bias.

Conclusions

Poor use of CURB-65 score resulted in an increase in admission of patients presenting with lower respiratory tract infection as recommended by The South African CAP guidelines but this finding must be considered in light of the poor predictability of severity in the setting of advanced HIV infection.

There is a high case fatality rate in patients presenting with LRTI in a high HIV prevalence setting, despite low CURB-65 score which might indicate that severity scores is not be a sensitive indicator for disease severity in the presence of HIV infection. Future research may consider adjustments and validation of severity scores for HIV infected individuals with low CD4 cell count. CAP and PTB remained a major cause of mortality and morbidity in HIV infected individuals especially in patients not on ART and with low CD4 cell count.

Acknowledgements

I would first like to thank my supervisor, Dr. Halima Dawood, whose expertise was invaluable in the formulating of the research topic and methodology in particular. I want to thank you for your excellent guidance and for all of the opportunities I was given to improve my research skills. I would like to acknowledge my colleagues and staff at Edendale hospital for their wonderful cooperation and collaboration. You supported me greatly and were always willing to help me. I would particularly like to single out Dr Douglas Wilson and the medical records team. I would also like to thank my husband Dr Adam for technical as well as moral support.

References

1. Wardlaw T, Salama P, Johansson EW, Mason E (2006) Pneumonia: the leading killer of children. Lancet 368: 1048-1050
2. Brown JD, Harnett J, Chambers R, Sato R (2018) The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr 18: 1-11
3. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58: 377-382
4. File Jr TM, Marrie TJ (2010) Burden of community-acquired pneumonia in North American adults. Postgrad Med 122: 130-141.
5. Madeddu G, Fiori ML, Mura MS (2010) Bacterial community-acquired pneumonia in HIV-infected patients. Curr Opin Pulm Med 16: 201-207.
6. Simonetti AF, Viasus D, Garcia-Vidal C, Carratalà J (2014) Management of community-acquired pneumonia in older adults. Ther Adv Infect Dis 2: 3-16.
7. Lim WS, Rodrigo C, Turner AM, Welham S, Calvert JM (2016) British Thoracic Society community-acquired pneumonia care bundle: results of a national implementation project. Thorax 71: 288-290.
8. Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, Society SAT (2017) South African guideline for...
the management of community-acquired pneumonia in adults. J Thorac Dis 9: 1469-1502.
9. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Whitney CG (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2: S27-S72.
10. Sterrettino C, Trifiró G, Lapi F, Pasqua A, Mazzaglia G, Piccinin C, Blasi F (2013) Burden of community-acquired pneumonia in Italian general practice. Eur Respir J 42: 1739-1742.
11. Georges H, Journaux C, Devos P, Alfandari S, Delannoy PY, Meybeck A, Leroy O (2013) Improvement in process of care and outcome in patients requiring intensive care unit admission for community acquired pneumonia. BMC Infect Dis 13: 1-10.
12. Touche C, Marrie TJ (1996) Comparison of community-acquired pneumonia requiring admission to hospital in HIV- and non-HIV-infected patients. Can J Infect Dis 7: 253-258.
13. Falzon D, Schüinemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K (2017) World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 49: 1602308.
14. Benito N, Moreno A, Miro JM, Torres A (2012) Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J 39: 730-745.
15. Choi MJ, Song YJ, Noh JY, Yoon JG, Lee SN, Heo JY, Kim WJ (2017) Disease burden of hospitalized community-acquired pneumonia in South Korea: analysis based on age and underlying medical conditions. Medicine (Baltimore) 96: e8429.
16. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D (2010) The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 7: e1000296.
17. Capelastegui A, Espara PP, Quintana JM, Areito I, Gorordo I, Egurrola M, Bilbao A (2006) Validation of a predictive rule for the management of community-acquired pneumonia. European Respiratory Journal 27: 151-157.
18. Man SY, Lee N, Ip M, Antonio GE, Chau SS, Mak P, Rainer TH (2007) Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 62: 348-353.
19. Chew KW, Yen IH, Li JZ, Winston LG (2011) Predictors of pneumonia severity in HIV-infected adults admitted to an Urban public hospital. AIDS Patient Care STDS 25: 273-277.
20. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ (2000) Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 132: 182-190.
21. Feikin DR, Feldman C, Schuchat A, Janoff EN (2004) Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 4: 445-455.
22. Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Schuchat A (2005) Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995—2000. J Infect Dis 191: 2038-2045.
23. Franzetti F, Grassini A, Piazza M, Degl’Innocenti M, Bandera A, Gazzola L, Gori A (2006) Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 34: 9-16.
24. Madeddu G, Porqueddu EM, Cambosu F, Saba F, Fois AG, Pirina P, Mura MS (2008) Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 36: 231-236.
25. Arnold FW, Wiemken TL, Peyrani P, Mirsaeidi M, Ramirez JA (2013) Outcomes in females hospitalised with community-acquired pneumonia are worse than in males. Eur Respir J 41: 1135-1140.
26. Quez JW, Fernandez LS, Moyano MG, Garrido IS, Bonilla AG, Crespo HG, Jorge RZ (2017) Differences in community acquired pneumonia according to gender. Eur 50: PA4101.
27. Gutiérrez F, Masiá M, Mirete C, Soldán B, Rodríguez JC, Padilla S, Martin-Hidalgo A (2006) The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 53: 166-174.
28. Kothe H, Bauer T, Marre R, Suttrop N, Welte T, Dalhoff K, Competence Network for Community-Acquired Pneumonia study group (2008) Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur 32: 139-146.
29. Iliyasu G, Habib AG, Mohammed AB, Borodoo MM (2015) Epidemiology and Clinical Outcomes of Community Acquired Pneumococcal Infection in North-West Nigeria. SSAJM 2: 79-84.
30. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
31. Marais B, Zumla A (2018) Advancing global tuberculosis control after the UNGA-HLM. Lancet 392: 1096-1097.
32. Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Aggarwal S, Garces S, Gathala M, Raviglione M (2013). The world tuberculosis report 2013. Geneva: World Health Organization.
33. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
34. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
35. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
36. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
37. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
38. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
39. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
40. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
41. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
42. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
43. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
44. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
45. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
46. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
47. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
48. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
49. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
50. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
51. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
52. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
53. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
54. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
55. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
56. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
57. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.
58. World Health Organization (2013) Global tuberculosis report 2013. Geneva: World Health Organization.